Bristol-Myers Squibb Company (NYSE:BMY) taking place in active move after raised 0.82% to the trading price of $61.76 in latest session.
GlancyProngay& Murray LLP (GPM) reported that an investigation on behalf of Bristol-Myers Squibb Company (NYSE:BMY) investors concerning the Company and its officers’ possible violations of federal securities laws.
On August 5, 2016, the Company reported that its CheckMate -026 trial investigating the use of Opdivo as monotherapy did not meet its primary endpoint of progression-free survival.
Then, on October 9, 2016, the Company further disclosed that in patients with ≥5% PD-L1 expression, the median progression-free survival was just 4.2 months with Opdivo compared to 5.9 months with platinum-based doublet chemotherapy.
Its 52-week range quite noticeable, lower range was $34.24% and hit highest level of $-6.56%. The overall volume in the last trading session was 1.36 Million shares. The firm shares 50 day moving average were calculated -0.65%. The firm’s institutional ownership remained 71.30% while insider ownership included 0.10%.
Organovo Holdings, Inc. (NASDAQ:ONVO) trade at $1.41 by knock down -2.59% in most recent trading session with share volume of 1.01 Million. Organovo Holdings, Inc. (ONVO) reported that the U.S. FDA granted orphan drug designation for the Company’s treatment of alpha-1 antitrypsin deficiency with its 3D bioprinted liver therapeutic tissue.
CEO, Organovo, Taylor J. Crouch said, “We are extremely pleased to receive orphan designation for our NovoTissues® treatment of A1AT. “The FDA’s rapid action recognizes the importance of developing regenerative medicine therapeutic applications, and mirrors our own urgency in addressing this devastating disease. With tens of thousands of patients being treated for inborn errors of metabolism (“IEMs”) in the U.S., and an annual cost per patient that exceeds $250,000 for drug therapy alone, these patient populations are in desperate need of new treatment options.”
Crouch concluded, “This is a critical milestone that supports our ongoing development of 3D bioprinted tissues for therapeutic use. We remain on track for filing an Investigational New Drug (“IND”) application with the FDA in calendar-year 2020, as we continue to conduct safety and dosing investigations in small animal disease models and move to defining and scoping IND enabling studies.”
The FDA Orphan Drug designation program provides incentives to sponsors that are developing therapies for rare diseases which affect fewer than 200,000 people in the United States. Organovo is now qualified to receive important benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs. The designation also includes a waiver of certain fees and a seven-year term of market exclusivity upon FDA approval of the orphan drug, and can provide for a more streamlined and cost-effective path through to commercialization.
The share is moved forward to its percent change from 52-week low of 6.71% and hanging back from its percent change from 52-week high of -64.24%. Shares price moved down from its 50 days moving average with -5.28% and remote positively from 200 days moving average with -37.59%.